Cannabis and Hemp Industry Investment News
Drug registration of NanaBis in Europe is a key part of Medlab’s plans and the SME qualification allows it to start the process. Medlab recently compl...
NanoStat refers to the delivery of the drug Atorvastatin using NanoCelle. NanoCelle delivers medicine in a tiny particle form in a spray into the mout...
() managing director & CEO Sean Hall speaks to Proactive Investors about the pharmaceutical company’s new European subsidiary and its development ...
Yesterday, Medlab revealed it had made progress expanding cannabis-based medicines into Europe. Shares in the company last traded at 39 cents ’s () di...
By having a European subsidiary, Medlab can save on drug registration fees. In Australia, Medlab has proceeded to stage II for its cannabis cancer tri...
Medlab Clinical () has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical...
The Sydney-based investor has demonstrated confidence in the company’s medical research strategy. Farjoy now holds almost 24 million shares, or 11.53%...
The company will now proceed with stage II of the human clinical trial. Stage I findings showed that NanaBis™ is safe indications confirm it helps wit...
's () Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle. Hall adds that the company is c...
The licence opens up potential international markets for its cannabis-based medicines. The two cannabis-based medicines are NanaBis™ and NanaBidial™ (...
NanoCelle™ is a mouth spray delivery system targeting cannabis-based medicines. Research is being conducted by University of Sydney’s Nano Institute (...
Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotic...
() CEO & managing director Dr. Sean Hall tells Proactive Investors, "probably one of the biggest things in medicine to date" is research into the ...
Focus of trial on safety and tolerability for oncology patients undergoing chemotherapy. Trial is for mucositis which affects +40% of chemotherapy pat...
Sydney-based investor has increased its interest to 10.51% through on-market purchases and placement participation. Medlab is focused on deliveries th...
() CEO & managing director Dr. Sean Hall speaks with Proactive Investors about the biotech's various research and development programs, focused on...
Medlab has already developed two cannabis-based medicines, NanaBis™ and NanaBidial™. NanaBis™ will be administered by medicine delivery platform, Nano...
The trial is designed to meet the Therapeutic Goods Administration's requirements for expedited drug approval. Annual cost of mental illness in Austra...
Medlab has approval to supply NanaBis™ under the TGA's Special Access Scheme. Earlier this year, the company raised $24 million in a placement () is o...
The trial will test the safety, efficacy and dose tolerance in cancer patients. Medlab is developing medicines for pain management Ltd () has commence...
